Conference Day One

Tuesday 31st October 2023

7:15 am Registration & Breakfast

8:10 am Chair’s Opening Remarks

• Gail Lewis Senior Principal Scientist, Genentech

8:30 am HER2-Directed Antibody Drug Conjugates in Breast Cancer: Recent Progress and Future Opportunities

• Zeshaan Rasheed Global Clinical, Late Phase Research, Development, Immuno-oncology Lead, AstraZeneca

9:00 am Industry Keynote: Next Steps for Enhertu to Reach More Patients with Unmet Needs Outside of Breast Cancer

• Gerold Meinhardt Vice President - Asset & Portfolio Management, Daiichi Sankyo

9:30 am Speed Networking & Morning Break

Maximizing HER2+ Primary Tumor Killing Through Various APIs, Methods of Drug Delivery & Immune System Engagement

10:30 am HER2 Gene Amplification & Overexpression in Non-Breast Carcinomas Compared to Breast Cancer

• Michael Press Professor / Harold E. Lee Chair in Cancer Research, University of Southern California

11:00 am Exploring Design Aspects for HER2-targeting ADCs

• Bob Lutz Chief Scientific Officer, Iksuda Therapeutics

11:30 am Utilizing Molecular Engineering Methods to Maximize Adoptive Cell Therapy in HER2 Cancers

• Francesco Marincola Chief Scientific Officer, Sonata Therapeutics

12:00 pm Lunch Break

1:00 pm Development from Preclinical to Clinical: Strengths of Immunological Therapeutics vs. Targeted Chemotherapy

• David Ferry Senior Vice President of Clinical Development, Dragonfly Therapeutics

1:30 pm Taking a Genomic Approach to HER2 Drug Design: A Case Study With ARX788

• Shawn Zhang Chief Scientific Officer, Ambrx

Testing Next Generation Therapeutics & Combinations for Specific Non-Breast HER2 Expressing Gut, Bowel and Lung Tumors With Well-Designed Indication-Agnostic Trials

2:00 pm Utilizing High Power Beta Radiation to Induce Tumor Cell Death

• Thom Tulip Chief Business Officer, Radiopharm Theranostics

2:30 pm Preclinical Antitumor Activity of a Multi-Modality Approach to Treating HER2 Tumors

• Haifeng Bao Chief Executive Officer, BiOnecure

3:00 pm Afternoon Break – Poster Session

4:00 pm Panel Discussion: Putting the Pieces Together – Identifying the Characteristics that HER2 Therapeutics Need in Their Design to Enable Them to Achieve Efficacious Results in Breast & Non-Breast Tumors?

• Sam Liu CEO, Shenzhen Enduring Biotech, Ltd.
• Shawn Zhang Chief Scientific Officer, Ambrx
• Bob Lutz Chief Scientific Officer, Iksuda Therapeutics

4:30 pm Treating HER2 Primary & Secondary Tumor Types Phase 1 Clinical Trial Results Overview

• Jei Chae Chief Business Development Officer, LegoChem Biosciences

5:00 pm Chair’s Closing Remarks

• Gail Lewis Senior Principal Scientist, Genentech

5:15 pm End of Day One